Desmethyl Celecoxib
CAS : 170569-87-6
Ref. 3D-VGA56987
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté |
Informations sur le produit
- Cox-2 Inhibitor, Ptpbs
- Cay10452
- Cay10454
- [3',6'-Bis(Acetyloxy)-3-Oxospiro[Isobenzofuran-1(3H),9'-[9H]Xanthen]-5-Yl]-2-[[(5Z,8Z,11Z,14Z)-1-Oxo-5,8,11,14-Eicosatetraenyl]Amino]Ethyl Ester Carbamic Acid
- 4-[5-Phenyl-3-(Trifluoromethyl)-1H-Pyrazol-1-Yl]Benzenesulfonamide
- 4-[5-Phenyl-3-(Trifluoromethyl)Pyrazol-1-Yl]Benzenesulfonamide
- Ptpbs
Celecoxib is a nonsteroidal anti-inflammatory drug that inhibits the production of prostaglandins by blocking the enzyme cyclooxygenase. It has been shown to inhibit the growth of carcinoma cell lines and induce apoptosis in these cells. Celecoxib has also been shown to inhibit phosphatases, which are enzymes that remove phosphate groups from other molecules. Molecular modeling studies have also suggested that celecoxib may act as a polymerase chain inhibitor, preventing DNA replication and transcription. The reaction mechanism is not well understood, but it appears to involve multiple steps with different types of reactants. Celecoxib has been shown to inhibit chlamydia growth and cause necrosis in chlamydia-infected mammalian cells. This drug has also been found to stimulate natural compounds such as matrix metalloproteinase and bowel disease acid formation that may be beneficial for bowel disease treatment. Celecoxib has also been shown to have anticancer effects on cancerous bowel disease cells by